Production of Anti-idiotype Antibody
We are professional in raising
anti-idiotype antibodies. Anti-idiotype antibodies are antibodies that have specific binding capabilities to an
idiotope of another antibody. Theidiotope is the unique set of antigenic determinants (epitopes) of the variable portion of the antibody. Here, it is the complementarity determining regions (CDR) that determine the antigen specificity of the antibody. In some cases it can be the actual antigen-binding site, and in some cases it may comprise variable region sequences outside of the antigen-binding site on the antibody itself. Therefore, anti-idiotype antibodies can be claimed as antibodies that target the antigen-binding site formed by the CDRs of the antibody. In theory, anti-idiotypic antibodies can mimic the original antigen and reproduce/inhibit the immune response raised by the original antigen depending on how to use the anti-idiotypic antibodies. Because of the resemblance of anti-idiotypic antibodies to the original antigen, anti-idiotypic antibodies can be used as the
anti-idiotypic vaccine to replace the antigen---if the original antigen is not available.
We employ three approaches to get anti-idiotype antibodies. The first one is to isolate V-regions specific antibodies from our human/mouse antibody libraries. If the original antigen, the target antibody and an iso-type matching control antibody are available, we can use our phage display antibody library screening services that allow isolation of human/mouse anti-idiotype antibodies that can recognize a conformational idiotope/epitope. If an iso-type matching control antibody is available, we can use it to deplete the binders [antibodies from our antibody library] that target the constant region of the heavy chain of the original antibody. However, we still have challenge in enriching the binders that target the antigen-binding site of the original antibody [from binders that target regions other than the specific idiotope]. For this reason, it will be great if the antigen is also available in a purified form.We offer these this service option at Creative BioLabs.
The second approach is to raise hybridoma clones in rats or mice using the target antibody as the imunogen and use iso-type matching control antibodies to do counter-selection. The third approach is to design a peptide according to the sequences of the variable domains to be used as the immunogen. We offer these two service options at